BeiGene, Ltd. (NASDAQ:BGNE) CFO Sells $67,920.80 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang sold 472 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $143.90, for a total value of $67,920.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Julia Aijun Wang also recently made the following trade(s):

• On Monday, June 24th, Julia Aijun Wang sold 899 shares of BeiGene stock. The stock was sold at an average price of $155.66, for a total value of $139,938.34.

BeiGene Trading Down 0.6 %

NASDAQ:BGNE opened at $147.04 on Friday. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $225.23. The business’s 50-day moving average price is $157.24 and its two-hundred day moving average price is $158.59. The company has a current ratio of 2.08, a quick ratio of 1.84 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $14.19 billion, a price-to-earnings ratio of -19.42 and a beta of 0.59.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.07) by $0.66. The company had revenue of $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The company’s revenue for the quarter was up 67.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.34) earnings per share. On average, equities analysts expect that BeiGene, Ltd. will post -8.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in shares of BeiGene in the first quarter valued at about $50,000. Toronto Dominion Bank increased its position in shares of BeiGene by 166.4% during the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after purchasing an additional 208 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of BeiGene during the 4th quarter worth approximately $98,000. PNC Financial Services Group Inc. boosted its holdings in shares of BeiGene by 123.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock valued at $132,000 after buying an additional 405 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of BeiGene in the fourth quarter valued at $183,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Sanford C. Bernstein cut their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research note on Wednesday, March 27th. TD Cowen upped their price target on BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, Bank of America cut their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $251.93.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.